Results about: colon cancer
Intricate signalling networks control cell division, differentiation, movement, organization and death. Understanding how cells read and transform these signals into changes in cell behaviour is a major research focus of our group.
IRB Barcelona has been awarded two ERC PoC grants to optimise and validate tools with potential clinical applications.
Angel R. Nebreda’s project seeks to develop treatments to reduce the cardiotoxicity caused by chemotherapy.
Eduard Batlle’s project will build a biobank of mouse tumour organoids with the aim to contribute to the treatment of patients with advanced colon cancer.
A new study by researchers at IRB Barcelona demonstrates that myeloid cells, which belong to the leucocyte family and form part of the innate immune system, use p38 protein signalling to support inflammation-associated colon cancer.
Published in EMBO Molecular Medicine, the study by Angel R. Nebreda suggests that inhibition of the p38 pathway in myeloid cells may be a useful therapeutic approach, especially in tumours associated with chronic inflammation.
In spite of the difference between the cell functions responsible for giving rise to a tumour and for the metastasis of this same tumour, studies at IRB Barcelona using the fly Drosophila melanogaster reveal that some genes can drive both phenomena.